Shire says it will appeal a decision invalidating a patent surrounding the controlled-release composition of its ulcerative colitis drug Lialda (mesalazine), according to an in-Pharma Technologist article.
The court ruled that a proposed generic of Lialda from Zydus Pharmaceuticals did not infringe on U.S. Patent No. 6,773,720. The story said this was one of four patents on Lialda that was scheduled to expire in June 2020.
Read the full story